Saphenous vein graft intervention: A review

Journal of Invasive Cardiology

Volumn 24, Issue 2, 2012, Pages 64-71

  Hindnavis, Vindhya ^a   Cho, Sung Hae ^a   Goldberg, Sheldon ^a  

^a HAHNEMANN UNIVERSITY HOSPITAL   (United States)

Author keywords

embolic protection devices; no reflow; plaque embolization; saphenous vein grafts

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; NICARDIPINE; THIENOPYRIDINE DERIVATIVE; VASODILATOR AGENT; VERAPAMIL;

ARTICLE; ARTIFICIAL EMBOLISM; ATHEROSCLEROTIC PLAQUE; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; DRUG MEGADOSE; EMBOLIC PROTECTION DEVICE; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; SAPHENOUS VEIN GRAFT; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT; VEIN GRAFT DISEASE;

EMBOLIC PROTECTION DEVICES; EMBOLISM, CHOLESTEROL; GRAFT OCCLUSION, VASCULAR; HUMANS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; SAPHENOUS VEIN; STENTS; VASODILATOR AGENTS;

EID: 84857462064     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (91)

1. Campeau L, Enjalbert M, Lesperance J, et al. The relation of risk factors to the development of atherosclerosis in saphenous vein bypass grafts and the progression of disease in the native circulation: a study 10 years after aortocoronary bypass surgery. N Engl J Med. 1984;311(21):1329-1332. (Pubitemid 15129601)
2. Bourassa MG. Fate of venous grafts: the past, the present, and the future. J Am Coll Cardiol. 1991;5(5):1081-1083.
3. Fitzgibbon GM, Kafka HP, Leach AJ, et al. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5065 grafts related to survival and reoperation in 1388 patients during 25 years. J Am Coll Cardiol. 1996;28(3):616-626. (Pubitemid 26288642)
4. Goldman S, Zadina K, Moritz T, et al. Long-term patency of saphenous vein and left internal mammary artery grafts after coronary artery bypass surgery: results from a Department of Veterans Affairs Cooperative Study. J Am Coll Cardiol. 2004 44(11);2149-2156. (Pubitemid 39576034)
5. Halabi AR, Alexander JH, Shaw LK, et al. Relation of early saphenous vein graft failure to outcomes following coronary artery bypass surgery. Am J Cardiol. 2005;96(9):1254-1259. (Pubitemid 41505404)
6. Motwani JG, Topol EJ. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation. 1998;97(9):916-931. (Pubitemid 28113931)
7. Cooper GJ, Underwood MJ, Deverall PB. Arterial and venous conduits for coronary artery bypass. Eur J Cardiothorac Surg. 1996;10(2):129-140. (Pubitemid 126690705)
8. Brilakis ES, Wang Ty, Rao SV, et al. Frequency and predictors of drug-eluting stent use in saphenous vein bypass graft percutaneous coronary interventions: a report from the American College of Cardiology National Cardiovascular Data CathPCI registry. JACC Cardiovasc Interv. 2010;3(10):1068-1073.
9. Coolong A, Baim DS, Kuntz RE, et al. Saphenous vein graft stenting and major adverse cardiac events: a predictive model derived from a pooled analysis of 3958 patients. Circulation. 2008;117(6):790-797. (Pubitemid 351640680)
10. Cameron A, Kemp Jr HG, Green GE. Reoperation for coronary artery disease: 10 years of clinical follow-up. Circulation. 1988;78(3 Pt 2):1158-1162.
11. Loop FD, Lytle BW, Cosgrove DM, et al. Reoperation for coronary atherosclerosis: changing practice in 2509 consecutive patients. Ann Surg. 1990;212(3):378-386. (Pubitemid 20289360)
12. Christenson JT, Schmuziger M, Simonet F. Reoperative coronary artery bypass procedures: risk factors for early mortality and late survival. Eur J Cardiothorac Surg. 1997;11(1):129-133. (Pubitemid 27076125)
13. de Feyter PJ, van Suylen RJ, de Jaegere PP, et al. Balloon angioplasty for the treatment of lesions in saphenous vein bypass grafts. J Am Coll Cardiol. 1993;21(7):1539-1549. (Pubitemid 23170424)
14. Morrison DA, Crowley ST, Veerakul G, et al. Percutaneous transluminal angioplasty of saphenous vein grafts for medically refractory unstable angina. J Am Coll Cardiol. 1994;23(5):1066-1070. (Pubitemid 24117136)
15. Plokker HW, Meester BH, Serruys PW. The Dutch experience in percutaneous transluminal angioplasty of narrowed saphenous veins used for aortocoronary arterial bypass. Am J Cardiol. 1991;67(5):361-366.
16. Savage MP, Douglas JS Jr, Fischman DL, et al. Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. Saphenous Vein De Novo Trial Investigators. N Engl J Med. 1997;337(11):740-747. (Pubitemid 27417973)
17. Hiscock M, Oqueli E, Dick R. Percutaneous saphenous vein graft intervention - a review. Heart Lung Circ. 2007;(16 Suppl 3):S51-S55. (Pubitemid 47233291)
18. Ge L, Lakovou L, Sangiorgi GM, et al. Treatment of saphenous vein graft lesions with drug eluting stents: immediate and midterm outcome. J Am Coll Cardiol. 2005;45(7):989-994. (Pubitemid 40432427)
19. Lee MS, Shah AP, Aragon J, et al. Drug-eluting stenting is superior to bare-metal stenting in saphenous vein grafts. Catheter Cardiovasc Interv. 2005;66(4):507-511. (Pubitemid 41779016)
20. Ramana RK, Ronan A, Cohoon K, et al. Long-term clinical outcomes of real-world experience using sirolimus-eluting stents in saphenous vein graft disease. Catheter Cardiovasc Interv. 2008;6(7):886-893. (Pubitemid 351951305)
21. Assali A, Raz Y, Vaknin-Assa H, et al. Beneficial 2-years results of drug-eluting stents in saphenous vein graft lesions. Eurointervention. 2008;4(1):108-114.
22. Chu W, Rha SW, Kuchulakanti PK, et al. Efficacy of sirolimus-eluting stents compared with bare-metal stents for saphenous vein graft intervention. Am J Cardiol. 2006;97(1):34-37. (Pubitemid 41828119)
23. Baldwin DE, Trost JC, Abbott J, et al. A comparison of drug-eluting and bare-metal stents for saphenous vein graft lesions: a report from the National Heart, Lung, and Blood Institute Dynamic Registry. J Am Coll Cardiol. 2008;51(Suppl):B23-B98.
24. Vignali L, Saia F, Manari A, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in the treatment of saphenous vein graft disease (results from the REgistro Regionale AngiopLastiche Emilia-Romagna Registry). Am J Cardiol. 2008;101(7):947-952.
25. Shishehbor MH, Hawi R, Singh IM, et al. Drug-eluting versus bare-metal stents for treating saphenous vein grafts. Am Heart J. 2009;158(4):637-643.
26. Vermeersch P, Agostoni P, Verheye S, et al. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in disease saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial. J Am Coll Cardiol. 2006;48(12):2423-2431. (Pubitemid 44895571)
27. Vermeersch P, Agostoni P, Verheye S, et al. Increased late mortality after sirolimus-eluting stents versus bare-metal stents in disease saphenous vein grafts: results from the randomized DELAYED RRISC Trial. J Am Coll Cardiol. 2007;50(3):261-267. (Pubitemid 47039289)
28. Brilakis ES, Lichtenwalter C, de Lemos JA, et al. A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial. J Am Coll Cardiol. 2009;53(11):919-928.
29. Brilakis ES, Lichtenwalter C, Abdel-karim AR, et al. Continued benefit from paclitaxel-eluting compared with bare-metal stent implantation in saphenous vein graft lesions during long-term follow-up of the SOS (Stenting of Saphenous Vein Grafts) trial. JACC Cardiovasc Interv. 2011;4(2):176-182.
30. Lee MS, Yang T, Kandzari DE, et al. Comparison by meta-analysis of drug-eluting stents and bare-metal stents for saphenous vein graft intervention. Am J Cardiol. 2010;105(8):1076-1082.
31. Joyal D, Filion KB, Eisenberg MJ. Effectiveness and safety of drug-eluting stents in vein grafts: a meta-analysis. Am Heart J. 2010;159(2):159-169.
32. Paradis JM, Belisle P, Joseph L, et al. Drug-eluting or bare-metal stents for the treatment of saphenous vein graft disease: a Bayesian meta-analysis. Circ Cardiovasc Interv. 2010;3(6):565-576.
33. Lupi A, Navarese EP, Lazzero M, et al. Drug-eluting stents vs. bare-metal stents in saphenous vein graft disease. Insights from a meta-analysis of 7,090 patients. Circ J. 2011;75(2):280-289.
34. Hakeem A, Helmy T, Munsif S, et al. Safety and efficacy of drug-eluting stents compared with bare-metal stents for saphenous vein graft interventions: a comprehensive meta-analysis of randomized trials and observational studies comprising 7,994 patients. Catheter Cardiovasc Interv. 2011;77(3):343-355.
35. Mamas MA, Foley J, Nair S, et al. A comparison of drug-eluting stents versus bare-metal stents in saphenous vein graft PCI outcomes: a meta-analysis. J Interv Cardiol. 2011;24(2):172-180.
36. Rodes-Cabau J, Bertrand OF, Larose E, et al. Comparison of plaque sealing with paclitaxel-eluting stents versus medical therapy for the treatment of moderate nonsignificant saphenous vein graft lesions: the moderate vein graft lesion stenting with the taxus stent and intravascular ultrasound (VELETI) pilot trial. Circulation. 2009;120(20):1978-1986.
37. Rodes-Cabau J, Bertrand OF, Larose E, et al. Plaque sealing with paclitaxel-eluting stents for the treatment of moderate non-significant saphenous vein graft lesions. Three-year follow-up of the VELETI trial. J Am Coll Cardiol. 2010;55:A193.E1809
38. Hong MK, Mehran R, Dangas G, et al. Creatine kinase-MB enzyme elevation following successful saphenous vein graft intervention is associated with late mortality. Circulation. 1999;100(24):2400-2405.
39. Califf RM, Abdelmegud AE, Kuntz RE, et al. Myonecrosis after revascularization procedures. J Am Coll Cardiol. 1998;31(2):241-251. (Pubitemid 28153440)
40. Kloner RA, Rude RE, Carlson N, et al. Ultrastructural evidence of microvascular damage and myocardial cell injury after coronary artery occlusion: which comes first? Circulation. 1980;62(5):945-952. (Pubitemid 11225959)
41. van Gaal WJ, Banning AP. Percutaneous coronary intervention and the no-reflow phenomenon. Expert Rev Cardiovasc Ther. 2007: 5(4);715-731. (Pubitemid 47050182)
42. De Luca G, Suryapranata H, Stone GW, et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA. 2005;293(14):1759-1765.
43. De Luca G, Suryapranata H, Stone GW, et al. Relationship between patient's risk profile and benefits in mortaliy from adjunctive abciximab to mechanical revascularization for ST-segment elevation myocardial infarction: a meta-regression analysis of randomized trials. J Am Coll Cardiol. 2006;47(3):685-686. (Pubitemid 43170866)
44. Karha J, Gurm HS, Rajagopal V, et al. Use of platelet glycoprotein IIb/IIIa inhibitors in saphenous vein graft percutaneous coronary intervention and clinical outcomes. Am J Cardiol. 2006;98(7):906-910. (Pubitemid 44402266)
45. Mathew V, Grill DE, Scott CG, et al. The influence of abciximab use on clinical outcome after aortocoronary vein graft interventions. J Am Coll Cardiol. 1999;34(4):1163-1169. (Pubitemid 29500555)
46. Roffi M, Mukherjee D, Chew DP, et al. Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials. Circulation. 2002;106(24):3063-3067. (Pubitemid 35440289)
47. Mak KH, Challapalli R, Eisenberg MJ, et al. Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts. EPIC Investigators. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications. Am J Cardiol. 1997;80(8):985-988. (Pubitemid 27459194)
48. Jonas M, Stone GW, Mehran R, et al. Platelet glycoprotein IIb/IIIa receptor inhibitos as adjunctive treatment during saphenous vein graft stenting: differential effects after randomization to occlusion or filter-based embolic protection. Eur Heart J. 2006;27(8):920-928.
49. Lee CH, Low A, Tai BC, et al. Pretreatment with intracoronary adenosine reduces the incidence of myonecrosis after non-urgent percutaneous coronary intervention: a prospective randomized study. Eur Heart J. 2007;28(1):19-25. (Pubitemid 46137813)
50. Desmet WJ, Dens J, Coussement P, Van de Werf F. Does adenosine prevent myocardial micronecrosis following percutaneous coronary intervention? The ADELINE pilot trial. ADEnosine LImit myocardial Necrosis. Heart. 2002;88(3):293-295. (Pubitemid 34913518)
51. Marzilli M, Orsini E, Marraccini P, Testa R. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation. 2000;101(18):2154-2159. (Pubitemid 30253043)
52. Stoel MG, Marques KM, de Cock CC, et al. High dose adenosine for suboptimal myocardial perfusion ater primary PCI: a randomized placebo-controlled pilot study. Catheter Cardiovasc Interv. 2008;71(3):283-289. (Pubitemid 351428141)
53. Assali AR, Sdringola S, Ghani M, et al. Intracoronary adenosine administered during percutaneous intervention in acute myocardial infarction and reduction in the incidence of "no reflow" phenomenon. Catheter Cardiovasc Interv. 2000;51(1):27-32.
54. Magaffey KW, Puma JA, Barbagelata NA, et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol. 1999;34(6):1711-1720.
55. Kloner RA, Forman MB, Gibbons RJ, Ross AM, Alexander RW, Stone GW. Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial. Eur Heart J. 2006;27(20):2376-2377.
56. Fischell TA, Carter AJ, Foster MT, et al. Reversal of "no reflow" during vein graft stenting using high velocity boluses of intracoronary adenosine. Cathet Cardiovasc Diagn. 1998;45(4):360-365. (Pubitemid 28541720)
57. Sdringola S, Assali A, Ghani M, et al. Adenosine use during aortocornary vein graft interventions reverses but does not prevent the slow-no reflow phenomenon. Catheter Cardiovasc Interv. 2000;51(4):394-399.
58. Watts JA, Hawes EM, Jenkins SH, et al. Effects of nisoldipine on the no-reflow phenomenon in globally ischemic rat hearts. J Cardiovasc Pharmacol. 1990:16(3):487-494. (Pubitemid 20254991)
59. Villari B, Ambrosio G, Gollino P, et al. The effects of calcium channel antagonist treatment and oxygen radical scavenging on infarct size and the no-reflow phenomenon in reperfused hearts. Am Heart J. 1993;125(1):11-23. (Pubitemid 23021620)
60. Taniyama Y, Ito H, Iwakura K, et al. Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction. J Am Coll Cardiol. 1997:30(5):1193-1199. (Pubitemid 27501434)
61. Fugit MD, Rubal BJ, Donovan DJ. Effects of intracoronary nicardipine, diltiazem and verapamil on coronary blood flow. J Invasive Cardiol. 2000:12(2):80-85.
62. Vijayalakshmi K, Whittaker VJ, Kunadian B, et al. Prospective, randomized, controlled trial to study the effect of intracoronary injection of verapamil and adenosine on coronary blood flow during percutaneous coronary intervention in patients with acute coronary syndromes. Heart. 2006:92(9):1278-1284. (Pubitemid 44298880)
63. Michaels AD, Appleby M, Otten MH, et al. Pretreatment with intragraft verapamil prior to percutaneous coronary intervention of saphenous vein graft lesions: results of the randomized, controlled vasodilator prevention on no-reflow (VAPOR) trial. J Invasive Cardiol. 2002;14(6):299-302. (Pubitemid 34651235)
64. Kaplan BM, Benzuly KH, Kinn JW, et al. Treatment of no-reflow in degenerate saphenous vein graft interventions: comparison of intracoronary verapamil and nitroglycerin. Cathet Cardiovasc Diagn. 1996;39(2):113-118.
65. Piana RN, Paik GY, Mosucci M, et al. Incidence and treatment of "no re-flow" after percutaneous coronary intervention. Circulation. 1994;89(6):2514-2518. (Pubitemid 24173664)
66. Resnic FS, Wainstein M, Lee MK, et al. No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention. Am Heart J. 2003;145(1):42-46. (Pubitemid 36034496)
67. Huang RI, Patel P, Walinsky, P, et al. Efficacy of intracoronary nicardipine in the treatment of no-reflow during percutaneous coronary intervention. Catheter Cardiovasc Interv. 2006;68(5):671-676. (Pubitemid 44721085)
68. Fischell TA, Subraya RG, Ashraf K, et al. "Pharmacologic" distal protection using prophylactic, intragraft nicardipine to prevent no-reflow and non-Q wave myocardial infarction during elective saphenous vein graft intervention. J Invasive Cardiol. 2007;19(2):58-62.
69. Abbo KM, Dooris M, Glazier S, etal. Features and outcome of no-reflow after percutaneous coronary intervention. Am J Cardiol. 1995;75(12):778-782.
70. Baldus S, Koster R, Elsner M, et al. Treatment of aortocoronary vein graft lesions with membrane-covered stents: a multicenter surveillance trial. Circulation. 2000;102(17):2024-2027.
71. Schachinger V, Hamm CW, Munzel T, et al; STING (STents IN Grafts) Investigators. A randomized trial of polytetrafluoroethylene-membrane-covered stents compared with conventional stents in aortocoronary saphenous vein grafts. J Am Coll Cardiol. 2003;42(8):1360-1369. (Pubitemid 37267273)
72. Stankovic G, Colombo A, Presbitero P, et al. Randomized Evaluation of polytetrafluoroethylene COVERed stent in Saphenous vein grafts (RECOVERS) Trial. Circulation. 2003;108(1):37-42.
73. Turco MA, Buchbinder M, Popma JJ, et al. Pivotal, randomized U.S. study of the Symbiot™ covered stent system in patients with saphenous vein graft disease: eight-month angiographic and clinical results from the Symbiot III trial. Catheter Cardiovasc Interv. 2006;68(3):379-388. (Pubitemid 44330675)
74. Stone GW, Goldberg S, O'Shaughnessy C, et al. 5-year follow-up of polytetrafluoroethylene-covered stents compared with bare-metal stents in aortocoronary saphenous vein grafts the randomized BARRICADE (barrier approach to restenosis: restrict intima to curtail adverse events) trial. JACC Cardiovasc Interv. 2011;4(3):300-309.
75. Baim DS, Wahr D, George B, et al. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aortocoronary bypass grafts. Circulation. 2002;105(11):1285-1290. (Pubitemid 34260417)
76. Carrozza Jr. JP, Mumma M, Breall JA, et al; the PRIDE Study Investigators. Randomized Evaluation of the TriActiv Balloon-Protection Flush and Extraction System for the Treatment of Saphenous Vein Graft Disease. J Am Coll Cardiol. 2005;46(9):1677-1683. (Pubitemid 41531622)
77. Stone G, Rogers C, Hermiller J, et al. Randomized comparison of distal protection with a filter-based catheter and a balloon occlusion and aspiration system during percutaneous intervention of diseased saphenous vein aorto-coronary bypass grafts. Circulation. 2003;108(5):548-553. (Pubitemid 36961168)
78. Cox DA. Stenting in saphenous vein grafts with distal protection using a second generation filter-based catheter: the combined BLAZE I and II registries. Paper presented at: Transcatheter Cardiovascular Therapeutics: Oct 2005; Washington, DC.
79. Dixon SR. Saphenous vein graft protection in a distal embolic protection randomized trial. Paper presented at: Transcatheter Cardiovascular Therapeutics; Oct 2005; Washington, DC.
80. Kereiakes DJ, Turco MA, Breall J, et al. A novel filter-based distal embolic protection device for percutaneous intervention of saphenous vein graft lesions: results of the AMEthyst randomized controlled trial. JACC Cardiovasc Interv. 2008;1(3):248-257. (Pubitemid 351804180)
81. Mauri L, Cox DA, Hermiller J, et al. The PROXIMAL trial: proximal protection during saphenous vein graft intervention using the Proxis embolic protection system: a randomized, prospective, multicenter trial. J Am Coll Cardiol. 2007;50(15):1142-1449.
82. Smith Jr SC, Feldman TE, Hirshfeld Jr JW, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2006;113(7):E166-E286.
83. Mehta SK, Frutkin AD, Milford-Beland S, et al. Utilization of distal embolic protection in saphenous vein graft interventions (an analysis of 19,546 patients in the American College of Cardiology-National Cardiovascular Data Registry). Am J Cardiol. 2007;100:1114-1118. (Pubitemid 47404467)
84. Kohsaka S, Makaryus AN. Coronary angiography using noninvasive imaging techniques of cardiac CT and MRI. Curr Cardiol Rev. 2008;4(4):323-330.
85. Schlosser T, Konorza T, Hunold P, et al. Noninvasive visualization of coronary artery bypass grafts using 16-detetor row computed tomography. J Am Coll Cardiol. 2004;44(6):1224-1229. (Pubitemid 39213969)
86. Safian RD, Freed MS, eds. The Manual of Interventional Cardiology. Royal Oak, MI: Physicians Press, 2001.
87. Collaborative overview of randomized trials of antiplatelet therapy - II: maintenance of vascular graft or arterial patency by antiplatelet therapy. Antiplatelet Trialists' Collaboration. BMJ. 1994;308(6922):159-168.
88. Gavaghan TP, Gebski V, Baron DW. Immediate postoperative aspirin improves vein graft patency early and late after coronary artery bypass graft surgery. A placebo-controlled, randomized study. Circulation. 1991;83(5):1526-1533.
89. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. The Post Coronary Artery Bypass Graft Trial Investigators. N Engl J Med. 1997;336(3):153-162.
90. Erratum in: N Engl J Med. 1997;337(25):1859.
91. Domanski MJ, Borkowf CB, Campeau L, et al. Prognostic factors for atherosclerosis progression in saphenous vein grafts: post-CABG trial. J Am Coll Cardiol. 2000;36(6):1877-1883.